Morgan Paul T, Ellis Tanith-Jade, Smeuninx Benoit, Breen Leigh, Kinsey Laura, Tomlinson Owen W, White Helen, Caley Laura R, Peckham Daniel G
Department of Sport and Exercise Sciences, Institute of Sport, Manchester Metropolitan University, 99 Oxford Road, Manchester, UK.
Monash Institute of Pharmacological Sciences, Monash University, Parkville, VIC, Australia.
Br J Nutr. 2025 Jun 28;133(12):1497-1505. doi: 10.1017/S0007114525103760. Epub 2025 Jun 30.
The RDA for dietary protein is likely insufficient for individuals with cystic fibrosis (CF). This study sought to characterise protein intake and diet quality in adults with cystic fibrosis (awCF), before and after elexacaftor/tezacaftor/ivacaftor (ETI) therapy, compared with healthy controls. Dietary intake was assessed by diet diary in awCF at baseline (BL, 40) and at follow-up > 3 months post ETI therapy (follow-up (FUP), 40) and in age-matched healthy controls (CON, 80) free from known disease at a single time point. Protein intake dose and daily distribution, protein quality, protein source and overall diet quality were calculated for each participant. Both CON (1·39 (sd 0·47) g·kg·day) and CF (BL: 1·44 (sd 0·52) g·kg·day, FUP: 1·12 (sd 0·32) g·kg·day) had a higher mean daily protein intake than the protein RDA of 0·75g·kg·day. There was a significant reduction in daily protein intake in the CF group at FUP ( = 0·0003, = 0·73), with levels below the alternative suggested dietary intake of ≥ 1·2 g·kg·day. There were no sex differences or noticeable effects on protein quality or source following the commencement of ETI therapy when compared with CON (all > 0·05), although overall diet quality decreased between time points ( 0·027, = 0·57). The observed reduction in daily protein intake in the present cohort emphasises the importance of ensuring appropriate dietary protein intake to promote healthy ageing in adults with CF. More research is needed to evidence base dietary protein requirements in this at-risk population.
对于囊性纤维化（CF）患者而言，膳食蛋白质的推荐膳食摄入量（RDA）可能并不充足。本研究旨在对接受依列卡福/替扎卡福/依伐卡福（ETI）治疗前后的成年囊性纤维化患者（awCF）的蛋白质摄入量和饮食质量进行特征分析，并与健康对照者进行比较。通过饮食日记评估awCF患者在基线期（BL，40例）和ETI治疗后3个月以上随访期（随访期（FUP），40例）的膳食摄入量，以及在单一时间点选取的年龄匹配且无已知疾病的健康对照者（CON，80例）的膳食摄入量。计算每位参与者的蛋白质摄入剂量和每日分布、蛋白质质量、蛋白质来源及总体饮食质量。CON组（1.39（标准差0.47）g·kg·天）和CF组（BL：1.44（标准差0.52）g·kg·天，FUP：1.12（标准差0.32）g·kg·天）的每日平均蛋白质摄入量均高于蛋白质RDA的0.75g·kg·天。CF组在FUP时的每日蛋白质摄入量显著降低（P = 0.0003，效应量 = 0.73），且低于建议的替代膳食摄入量≥1.2 g·kg·天。与CON组相比，ETI治疗开始后，在蛋白质质量或来源方面没有性别差异或明显影响（所有P>0.05），尽管两个时间点之间总体饮食质量有所下降（P = 0.027，效应量 = 0.57）。本队列中观察到的每日蛋白质摄入量的减少强调了确保适当膳食蛋白质摄入量对促进成年CF患者健康衰老的重要性。需要更多研究来为这一高危人群的膳食蛋白质需求提供循证依据。
